CORONA Remedies

CORONA

Q: How strong is CORONA Remedies balance sheet?

Balance sheet of CORONA Remedies is strong.But short term working capital might become an issue for this company.

Q: Is the debt of CORONA Remedies increasing or decreasing?

Yes, The net debt of CORONA Remedies is increasing.Latest net debt of CORONA Remedies is -₹14.38 Crs as of Sep-25.This is greater than Mar-25 when it was -₹73.15 Crs.

Q: Is CORONA Remedies stock expensive?

There is insufficient historical data to gauge this.Latest PE of CORONA Remedies is 62.89

Price

Small Cap

₹9,398 Cr.

New to Zerodha? Sign-up for free.

CORONA Remedies Ltd. develops, manufactures, and markets prescription and OTC medicines across therapeutic areas including cardiology, diabetology, gastroenterology, dermatology, respiratory care, neurology, pain management, and nutraceuticals.

CORONA Remedies Ltd. develops, manufactures, and markets prescription and OTC medicines across ther… More

Low

1,336

52W Range

High

1,560

62.89

Sector PE

28.58

P/B

13.33

Div.Yield

ROE

24.65%

EBIDTA

ROCE

30.24

EPS

6.75

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

CORONA
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

CORONA
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Corona Remedies Dec-Quarter Consol Net Profit 412.7 Million Rupees

Feb 02, 2026

Corona Remedies Secures EAEU–GMP Certification

Jan 21, 2026

Events:

Quarterly Results

Announcement Date

Feb 02, 2026

Lockin Period Expiry (Anchor)

Date

Jan 09, 2026

Quarterly Results

Announcement Date

Jan 02, 2026

More Small Cap Ideas

See similar 'Small' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does CORONA Remedies do?

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product portfolio comprises brands that cater to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory.

Who are the competitors of CORONA Remedies?

CORONA Remedies major competitors are Abbott India, Alkem Laboratories, Eris Lifesciences, Glaxosmithkline Phar, JB Chem & Pharma, Mankind Pharma, Pfizer. Market Cap of CORONA Remedies is ₹9,343 Crs. While the median market cap of its peers are ₹29,813 Crs.

Is CORONA Remedies financially stable compared to its competitors?

CORONA Remedies seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does CORONA Remedies pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. CORONA Remedies latest dividend payout ratio is 29.92% and 3yr average dividend payout ratio is 24.96%

How has CORONA Remedies allocated its funds?

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

How strong is CORONA Remedies balance sheet?

Balance sheet of CORONA Remedies is strong. But short term working capital might become an issue for this company.

Is the profitablity of CORONA Remedies improving?

Yes, profit is increasing. The profit of CORONA Remedies is ₹181 Crs for TTM, ₹149 Crs for Mar 2025 and ₹90.5 Crs for Mar 2024.

Is the debt of CORONA Remedies increasing or decreasing?

Yes, The net debt of CORONA Remedies is increasing. Latest net debt of CORONA Remedies is -₹14.38 Crs as of Sep-25. This is greater than Mar-25 when it was -₹73.15 Crs.

Is CORONA Remedies stock expensive?

There is insufficient historical data to gauge this. Latest PE of CORONA Remedies is 62.89

Has the share price of CORONA Remedies grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about CORONA Remedies?

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in CORONA Remedies is 69.0% and last quarter promoter holding is 69.0%.

Are mutual funds buying/selling CORONA Remedies?

The mutual fund holding of CORONA Remedies is stable. The current mutual fund holding in CORONA Remedies is 2.44% while previous quarter holding is 2.44%.

CORONA

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

Corona Remedies Dec-Quarter Consol Net Profit 412.7 Million Rupees

Corona Remedies Secures EAEU–GMP Certification

Events:

Quarterly Results

Lockin Period Expiry (Anchor)

Quarterly Results

More Small Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does CORONA Remedies do?

Who are the competitors of CORONA Remedies?

Is CORONA Remedies financially stable compared to its competitors?

Does CORONA Remedies pay decent dividends?

How has CORONA Remedies allocated its funds?

How strong is CORONA Remedies balance sheet?

Is the profitablity of CORONA Remedies improving?

Is the debt of CORONA Remedies increasing or decreasing?

Is CORONA Remedies stock expensive?

Has the share price of CORONA Remedies grown faster than its competition?

Is the promoter bullish about CORONA Remedies?

Are mutual funds buying/selling CORONA Remedies?